Finance

NUBURU receives NYSE American warning over delayed disclosure

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

The turnaround of this beaten-up Dow stock looks for real, says Katie Stockton

Bonds have taken control of the markets’ narrative – analyst (SP500:)